Online citations, reference lists, and bibliographies.

Immunomodulatory Drugs Revlimid® (lenalidomide) And CC-4047 Induce Apoptosis Of Both Hematological And Solid Tumor Cells Through NK Cell Activation

Dan Zhu, Laura G. Corral, Yuedi W. Fleming, Bernd Stein
Published 2008 · Biology, Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
Revlimid® (Lenalidomide, CC-5013) and CC-4047 are IMiDs® immunomodulatory drugs that have been described as having immunomodulatory properties and anti-tumor activity. Here we report proapoptotic effects of CC-5013 and CC-4047 on tumor cells in a co-culture model of PBMC and tumor cells. CC-5013 and CC-4047 enhanced PBMC activity leading to tumor cell apoptosis in K562/PBMC co-culture model. We also demonstrate that the natural killer (NK) cell population of PBMC was essential in inducing K562 apoptosis. Increases of NK and natural killer T (NKT) cell populations by CC-5013 and CC-4047 was observed along with modulation of NK cell CD56 adhesion marker. In addition, our data indicate that NK activation by CC-4047 was dependent on other cell types of PBMC. We expanded the application of K562/PBMC co-culture model to other hematological and solid tumors. In Raji/PBMC co-culture model, CC-5013 and CC-4047 dose-dependently augmented tumor cell apoptosis. Pre-treatment of Raji cells with Rituximab further enhanced apoptosis induced by CC-5013 or CC-4047-treated PBMC. Moreover, CC-5013 and CC-4047 significantly increased PC-3 prostate cancer cell apoptosis in PC-3/PBMC co-culture, either as single agent or in combination with Docetaxel. Together, the results reveal that co-culture models are suitable cellular systems to assess anti-tumor activities of these compounds. Our findings support clinical evaluation of CC-5013 and CC-4047 in relapsed NHL with Rituximab and in prostate cancer with Docetaxel.
This paper references
10.1016/S1046-2023(03)00123-3
The flow cytometric PKH-26 assay for the determination of T-cell mediated cytotoxic activity.
Karin Fischer (2003)
10.1182/blood.V99.12.4525
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.
Nicholas Mitsiades (2002)
10.1053/j.seminoncol.2005.06.020
Emerging data on IMiDs in the treatment of myelodysplastic syndromes (MDS).
Alan F List (2005)
10.1158/0008-5472.CAN-05-2086
Anti-prostate stem cell antigen monoclonal antibody 1G8 induces cell death in vitro and inhibits tumor growth in vivo via a Fc-independent mechanism.
Zhennan Gu (2005)
Phase I Evaluation ofJ 591 as a Vascular Targeting Agent in Progressive SolidTumors
MichaelJ. Morris (2007)
10.1158/1078-0432.CCR-05-0577
Immunomodulatory Drug CC-5013 or CC-4047 and Rituximab Enhance Antitumor Activity in a Severe Combined Immunodeficient Mouse Lymphoma Model
Francisco J Hernandez-Ilizaliturri (2005)
10.1038/sj.leu.2402745
Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo
Suzanne Lentzsch (2003)
10.1097/01.JTO.0000268679.33238.67
Phase I Study of Lenalidomide in Solid Tumors
Antonius A. Miller (2007)
10.1038/sj.leu.2404398
Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2V617F positive, del(5)(q13q33) myelodysplastic syndrome
Ruben Mesa (2006)
10.1182/blood.V98.1.210
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
Faith Davies (2001)
Human natural killer cell adhesion molecules. Differential expression after activation and participation in cytolysis.
Michael J Robertson (1990)
10.1517/13543784.14.1.45
Thalidomide and immunomodulatory drugs in the treatment of cancer
Aristotle Bamias (2005)
10.1182/blood-2004-06-2281
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma.
Noopur S. Raje (2004)
A phase I open-label study using lenalidomide and docetaxel in androgen independent prostate cancer (AIPC)
RA Moss (2007)
10.1084/jem.175.3.779
Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF
Michael J Robertson (1992)
10.1158/0008-5472.CAN-06-2317
Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells.
Dominique Verhelle (2007)
10.1089/jir.2005.25.604
Immunomodulatory drugs (IMiDs) increase the production of IL-2 from stimulated T cells by increasing PKC-theta activation and enhancing the DNA-binding activity of AP-1 but not NF-kappaB, OCT-1, or NF-AT.
Faribourz Payvandi (2005)
10.1038/sj.bjc.6601579
Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers
Justin Blake Bartlett (2004)
10.2174/1568008033340207
Thalidomide derived immunomodulatory drugs (IMiDs) as potential therapeutic agents.
J Blake Marriott (2003)
10.1136/ard.58.2008.i107
Immunomodulation by thalidomide and thalidomide analogues
Laura G. Corral (1999)
10.1111/j.1365-3083.2006.01883.x
Induction of CD16+ CD56bright NK cells with antitumour cytotoxicity not only from CD16- CD56bright NK Cells but also from CD16- CD56dim NK cells.
Eiji Takahashi (2007)
10.1200/jco.2007.25.18_suppl.8052
Preliminary results from a phase II study of lenalidomide oral monotherapy in relapsed/refractory aggressive non-Hodgkin lymphoma
Peter H. Wiernik (2007)
10.1182/BLOOD-2007-08-107292
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.
Yu-Tzu Tai (2008)
10.1182/blood.V96.9.2943
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.
Teru Hideshima (2000)
10.1158/0008-5472.CAN-05-1657
Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications.
Yu-Tzu Tai (2005)
10.1016/j.mvr.2005.01.002
Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro.
Keith Dredge (2005)
IMiDs enhance tumor cell apoptosis in tumor/PBMC co-cultures
Yuedi Wang (2005)
10.1038/nrc1323
The evolution of thalidomide and its IMiD derivatives as anticancer agents
J. Blake Bartlett (2004)
10.1038/sj.bjc.6600607
Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects
Keith Dredge (2002)
Comparative studies of human FcRIII-positive and negative natural killer cells.
Arnon Nagler (1989)
Czucz- man MS
FJ Hernandez-Ilizaliturri (2005)
10.1517/14656566.8.4.497
The evolving role of lenalidomide in the treatment of hematologic malignancies
Efstathios Kastritis (2007)
10.1038/sj.bjc.6602774
Recent clinical studies of the immunomodulatory drug (IMiD®) lenalidomide
Justin Blake Bartlett (2005)
10.1200/jco.2007.25.18_suppl.3023
Lenalidomide and pomalidomide strongly enhance tumor cell killing in vitro during antibody-dependent cellular cytotoxicity (ADCC) mediated by trastuzumab, cetuximab and rituximab
Justin Blake Bartlett (2007)
arising from JAK 2 ( V 617 F ) positive , del ( 5 ) ( q 13 q 33 ) myelodysplastic syndrome
AA Miller (2007)
10.1016/j.beha.2005.01.010
Novel biological therapies for the treatment of multiple myeloma.
Paul G Richardson (2005)
10.1124/jpet.102.048496
Enhancement of Cytokine Production and AP-1 Transcriptional Activity in T Cells by Thalidomide-Related Immunomodulatory Drugs
Peter H. Schafer (2003)
10.1111/j.1365-2141.2004.05286.x
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.
Toshiaki Hayashi (2005)
10.1016/0065-2571(84)90007-4
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.
Ting Chao Chou (1984)
10.1186/1742-4933-3-10
Ageing is associated with a decline in peripheral blood CD56bright NK cells
Shivani M Chidrawar (2006)



This paper is referenced by
10.1038/leu.2016.255
A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab as Maintenance Therapy Following Standard Chemotherapy for Patients with High/High-intermediate risk Diffuse Large B-Cell Lymphoma
Nishitha M. Reddy (2017)
10.3109/10428194.2012.676175
The role of natural killer cells in immunity against multiple myeloma
James Godfrey (2012)
10.2217/fon-2019-0116
Natural killer cells: a Review of biology, therapeutic potential and challenges in treatment of solid tumors.
Khalil Choucair (2019)
10.1093/annonc/mdp111
Phase II study of sunitinib in men with advanced prostate cancer.
M. Dror Michaelson (2009)
10.1158/2326-6066.CIR-15-0291
Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells
Rebekah L. Browning (2016)
10.1159/000336481
PSA Response to Lenalidomide Therapy in a Pre-Treated Patient with Metastatic Prostate Cancer Refractory to Hormones and Chemotherapy: A Case Report
Joan Manel Gasent Blesa (2012)
10.2217/imt.14.93
Emerging immunotherapy and strategies directly targeting B cells for the treatment of diffuse large B-cell lymphoma.
Magdalena Witkowska (2015)
10.1158/1535-7163.MCT-15-0879
A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer
Erin M. Bertino (2016)
10.1111/bjh.14570
Phase I study of cord blood‐derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma
Nina Shah (2017)
NK cell biology : An update and future directions
Kerry S Campbell (2013)
10.1007/s10147-011-0243-1
A prospective clinical trial of lenalidomide with topotecan in women with advanced epithelial ovarian carcinoma
Jori S. Carter (2011)
10.1158/1078-0432.CCR-11-2186
Cancer Dormancy: A Model of Early Dissemination and Late Cancer Recurrence
David Páez (2011)
10.1016/j.hoc.2013.10.004
Customized targeted therapy in Hodgkin lymphoma: hype or hope?
Catherine Diefenbach (2014)
10.1182/blood-2012-06-438028
A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma.
D. Michael Benson (2012)
10.1371/journal.pone.0080437
Immunomodulatory Effects in a Phase II Study of Lenalidomide Combined with Cetuximab in Refractory KRAS-Mutant Metastatic Colorectal Cancer Patients
Anita K Gandhi (2013)
10.1124/jpet.114.215251
Modeling and Simulation to Probe the Pharmacokinetic Disposition of Pomalidomide R- and S-Enantiomers
Yan Li (2014)
10.1177/2040620718775629
Update on the role of lenalidomide in patients with multiple myeloma
Sarah A Holstein (2018)
A phase 1 trial of the anti-KIR antibody IPH 2101 in patients with relapsed / refractory multiple myeloma
D. Michael Benson (2012)
10.1182/blood-2010-06-255067
Novel therapeutic agents for B-cell lymphoma: developing rational combinations.
Craig B. Reeder (2011)
Hodgkin lymphoma: targeting the tumor microenvironment as a therapeutic strategy.
Francesca Montanari (2015)
10.1002/cpdd.470
An Open‐Label, Phase 1 Study to Assess the Effects of Hepatic Impairment on Pomalidomide Pharmacokinetics
Yan Li (2019)
10.3109/10428194.2012.728597
Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma
Yuan Xiao Zhu (2013)
10.2147/OTT.S34498
Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma
Evangelos Terpos (2013)
10.1254/FPJ.148.154
ポマリドミド(ポマリスト®カプセル1 mg/2 mg/3 mg/4 mg)の薬理学的/薬物動態学的特性および臨床試験成績
Kaoru Torigoe (2016)
10.1179/1973947814Y.0000000201
Impact of pomalidomide therapy in multiple myeloma: a recent survey
Arvind Kumar (2014)
10.1111/cas.14418
Pharmacological targeting of natural killer cells for cancer immunotherapy
Kiho Miyazato (2020)
10.1016/j.cellimm.2010.06.003
Lenalidomide down regulates the production of interferon-gamma and the expression of inhibitory cytotoxic receptors of human Natural Killer cells.
Nicolas Dauguet (2010)
10.1097/JTO.0b013e318282707b
A Phase I Study of Pomalidomide (CC-4047) in Combination with Cisplatin and Etoposide in Patients with Extensive-Stage Small-Cell Lung Cancer
Peter Michael Ellis (2013)
10.1158/1535-7163.MCT-17-0673
Phase I Dose-Escalation Study of Anti–CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers
Divya Sakamuri (2017)
Lymphoma and Chronic Lymphocytic Leukemias Mantle Cell Lymphoma : Individualizing Therapy
Graham P. Collins (2014)
10.1182/blood-2011-03-339077
Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.
Xavier C. Badoux (2011)
10.1517/17425255.2013.827169
Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma
Francesca Gay (2013)
See more
Semantic Scholar Logo Some data provided by SemanticScholar